Gliotoxin

Gliotoxin is a sulfur-containing mycotoxin that belongs to a class of naturally occurring 2,5-diketopiperazines produced by several species of fungi, especially those of marine origin. It is the most prominent member of the epipolythiopiperazines, a large class of natural products featuring a diketopiperazine with di- or polysulfide linkage. These highly bioactive compounds have been the subject of numerous studies aimed at new therapeutics. Gliotoxin was originally isolated from "Gliocladium fimbriatum", and was named accordingly. It is an epipolythiodioxopiperazine metabolite.
Occurrence.
The compound is produced by human pathogens such as "Aspergillus fumigatus", and also by species of "Trichoderma" and "Penicillium". Gliotoxin has also been reported from yeasts of the genus "Candida", but results from other studies have cast doubt on the production of this metabolite by "Candida" fungi.
Mechanism of action.
Gliotoxin is suspected to be an important virulence factor in "Aspergillus" fungus. Gliotoxin possesses immunosuppressive properties that may suppress and cause apoptosis in certain cells of the immune system, including neutrophils, eosinophils, granulocytes, macrophages, and thymocytes. Specifically, neutrophils exposed to gliotoxin release less reactive oxygen species (ROS) and complete fewer phagocytic activities. Gliotoxin is also believed to interfere with T-cell activation. Additionally, gliotoxin acts as an inhibitor of farnesyl transferase. It noncompetitively inhibits the chymotrypsin-like activity of the 20S proteasome.
In vivo gliotoxin displays anti-inflammatory activity. It was investigated as an antibiotic and antifungal in the 1940s and as an antiviral agent. Gliotoxin inactivates many different enzymes, including nuclear factor-κB (NF-κB), NADPH oxidase, and glutaredoxin. The inhibition of NF-κB leads prevents cytokine release and induction of the inflammatory response.
The immunosuppressive properties of gliotoxin are due to the disulfide bridge within its structure. Interactions occur between sulfur molecules that make up the disulfide bridge and thiol groups contained in cysteine residues. Gliotoxin acts by blocking thiol residues in the cell membrane. Gliotoxin also activates a member of the Bcl-2 family called Bak in order to mediate cell apoptosis. Activated Bak then causes the release of ROS, which form pores within the mitochondrial membrane. These pores allow the release of cytochrome C and AIF, which initiate apoptosis within the cell.
Biosynthesis.
In "Aspergillus fumigatus", the enzymes needed for gliotoxin biosynthesis are encoded in 13 genes within the gli gene cluster. When this gene cluster is activated, these enzymes mediate the production of gliotoxin from serine and phenylalanine residues.
Enzymes Involved in Biosynthesis (in order of activity) 
Regulation of Biosynthesis
Some gliotoxin molecules are not secreted by GliA and remain in the cell. This intracellular gliotoxin activates the transcription factor GliZ, facilitating "gli" gene cluster expression, and an enzyme called GtmA. GtmA acts as a negative regulator for gliotoxin biosynthesis by adding methyl groups to the two sulfur residues on the dithiol gliotoxin intermediate. These additions prevent the formation of the disulfide 
bridge by GliT, inhibiting gliotoxin formation.
Exposure and health effects.
Environmental exposure.
Exposure to fungal species that secrete gliotoxin is common because airborne "Aspergillus" fungal spores are ubiquitous in many environments. Regular environmental exposure does not typically cause illness, but can cause serious infections in immunosuppressed individuals or those suffering from chronic respiratory illnesses. Infections caused by "Aspergillus" fungus are called aspergillosis. There are many types of aspergillosis, but infections typically affect the lungs or the sinuses.
Gliotoxin is hypothesized to be an important virulence factor in "Aspergillus fumigatus". Experiments have demonstrated that gliotoxin is isolated in the highest concentrations from "Aspergillus fumigatus" in comparison to other "Aspergillus" species. This species of fungi is the most common cause of aspergillosis in humans. Gliotoxin is also the only toxin that has been isolated from the sera of patients suffering from invasive aspergillosis. These results suggest a link between gliotoxin secretion and fungal pathogenicity.
While not enough data exists to definitively tie chronic gliotoxin exposure to the development of cancer, chronic exposure to other immunosuppressive agents has been linked to the development of lymphomas and mammary tumors. Individuals taking immunosuppressive medications or with previous or current exposure to chemotherapy radiation are at higher risk for the development of these tumors.
Clinical exposure.
Gliotoxin is toxic if swallowed or inhaled, and can cause skin and eye irritation if exposure occurs to these areas. The oral of gliotoxin is 67 mg/kg. Acute symptoms of gliotoxin start rapidly after ingestion.